140 related articles for article (PubMed ID: 26048718)
1. Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.
Ingersoll SB; Ahmad S; McGann HC; Banks RK; Stavitzski NM; Srivastava M; Ali G; Finkler NJ; Edwards JR; Holloway RW
Mol Cell Biochem; 2015 Sep; 407(1-2):281-7. PubMed ID: 26048718
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy.
Ingersoll SB; Patel S; Caballero L; Ahmad S; Edwards D; Holloway RW; Edwards JR
Gynecol Oncol; 2009 Jan; 112(1):192-8. PubMed ID: 18995891
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of a fluorescent highly tumorigenic ovarian cancer line to test cellular therapy in experimental models.
Ingersoll SB; Ahmad S; Stoltzfus GP; Patel S; Radi MJ; Finkler NJ; Edwards JR; Holloway RW
Int J Gynecol Cancer; 2011 Apr; 21(3):457-65. PubMed ID: 21430454
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer.
Green DS; Husain SR; Johnson CL; Sato Y; Han J; Joshi B; Hewitt SM; Puri RK; Zoon KC
Immunotherapy; 2019 Apr; 11(6):483-496. PubMed ID: 30860437
[TBL] [Abstract][Full Text] [Related]
5. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors.
Nakashima H; Miyake K; Clark CR; Bekisz J; Finbloom J; Husain SR; Baron S; Puri RK; Zoon KC
Cancer Immunol Immunother; 2012 Jul; 61(7):1081-92. PubMed ID: 22159517
[TBL] [Abstract][Full Text] [Related]
8. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
11. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.
Martinez D; Palmer C; Simar D; Cameron BA; Nguyen N; Aggarwal V; Lloyd AR; Zekry A
Liver Int; 2015 Feb; 35(2):463-72. PubMed ID: 24461080
[TBL] [Abstract][Full Text] [Related]
13. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
Lee JM; Yoon SH; Kim HS; Kim SY; Sohn HJ; Oh ST; Oh IH; Kim TG
Cancer Gene Ther; 2010 Oct; 17(10):742-50. PubMed ID: 20559334
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron
Green DS; Nunes AT; David-Ocampo V; Ekwede IB; Houston ND; Highfill SL; Khuu H; Stroncek DF; Steinberg SM; Zoon KC; Annunziata CM
J Transl Med; 2018 Jul; 16(1):196. PubMed ID: 30012146
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors and ovarian cancer patients.
Ingersoll SB; Stoltzfus GP; Merchant MH; Ahmad S; Edwards CR; Ahmed A; Oyer JL; Finkler NJ; Holloway RW; Edwards JR
Cytotherapy; 2012 Jul; 14(6):716-23. PubMed ID: 22409787
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
18. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
[TBL] [Abstract][Full Text] [Related]
19. Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-alpha.
Tzai TS; Shiau AL; Wu CL; Chow NH; Tsai YS
Anticancer Res; 1998; 18(5A):3355-61. PubMed ID: 9858908
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Huang SF; Kim SJ; Lee AT; Karashima T; Bucana C; Kedar D; Sweeney P; Mian B; Fan D; Shepherd D; Fidler IJ; Dinney CP; Killion JJ
Cancer Res; 2002 Oct; 62(20):5720-6. PubMed ID: 12384530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
